An Introduction to Digestive Disorders
Inflammatory bowel disease is a term used to describe chronic, relapsing inflammatory disorders of the digestive tract. The major types are ulcerative colitis, which causes inflammation in the colon, and Crohn’s disease, which may affect any part of the digestive tract, from mouth to anus. Symptoms include abdominal pain, blood in the stool, irregular bowel habits, weight loss and fatigue. Established treatment options are surgery, aminosalicylates, corticosteroids, immunomodulators and anti-TNFα inhibitors; however, many patients will fail to respond or become refractory to these therapies. Emerging therapies include anti-integrin therapy, JAK1 inhibitors, sphingosine-1-phosphate receptor modulators, stem-cell transplant and faecal microbiota transplant.
Our supporting partners do not constitute an endorsement of the content on this page.
Digestive Disorders Content
UEG Young Talent Group – aims, key achievements and opportunities for early career gastroenterologists: Pilar Acedo
The UEG Young Talent Group (YTG) encourages young gastroenterologists to develop their careers through education, networking and training. We were delighted to catch up with UEG YTG Chair Dr. Pilar Acedo to discuss the training, education and professional opportunities available to young digestive healthcare specialists through UEG, the aims and key achievements of the UEG […]
Highlights from Digestive Disease Week 2023: Gil Y. Melmed
Digestive Disease Week took place between 6-9 May, in this touchIMMUNOLOGY interview, we caught up with our Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) around his personal highlights from this year’s conference including non-pivotal clinical trial data analysing established inflammatory bowel disease (IBD) therapies such as vedolizumab, data around the […]
Comparison study of upadacitinib and tofacitinib as induction treatment in ulcerative colitis: Gil Y. Melmed, DDW 2023
Upadacitinib and tofacitinib are both JAK inhibitors (JAKis) approved by the FDA for the treatment of ulcerative colitis. In this interview with Expert Faculty member Prof. Gil Y. Melmed (Cedars-Sinai, Los Angeles, CA, USA) we discuss the aims, design and findings from his study presented at DDW 2023, comparing the efficacy and safety of these […]
LIBERTY-EoE-TREET analysis looking at eosinophil count and histologic score: Margaret Collins, DDW 2023
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) investigated the efficacy and safety of dupilumab in eosinophilic esophagitis. In this interview we spoke with Dr. Margaret Collins (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA) around her analysis of the phase 3 study looking at the eosinophil count and histologic score at 24 weeks of dupilumab 300 […]
Dupilumab an approved monoclonal antibody for eosinophilic esophagitis: Margaret Collins, DDW 2023
Dupilumab, a fully human monoclonal antibody that works by blocking IL-4Rα, is currently approved for the treatment of eosinophilic esophagitis (EoE) in the USA and EU. It was a pleasure to talk with Dr. Margaret Collins (Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA) around the mechanism of action of dupilumab and the impact its […]
LIBERTY-EoE-TREET analysis looking at prior use of topical corticosteroids: Arjan Bredenoord, DDW 2023
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) evaluated the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic oesophagitis. We caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the part C subgroup analysis, which investigated the effect of prior topical corticosteroid use on the efficacy of […]
Dupilumab as a therapeutic option for eosinophilic oesophagitis: Arjan Bredenoord, DDW 2023
Dupilumab is a fully human monoclonal antibody that inhibits the interleukin-4 and interleukin-13 pathways, and has been approved for the treatment of eosinophilic oesophagitis in the USA and Europe. touchIMMUNOLOGY caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the burden of eosinophilic oesophagitis, limitations of current therapeutic options, […]
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Guselkumab: an investigational monoclonal antibody for ulcerative colitis: Jessica Allegretti, DDW 2023
Guselkumab is a fully human monoclonal antibody IL-23 p19 subunit antagonist currently being investigated in hard to treat, moderately to severely active ulcerative colitis. We were delighted to speak with Dr Jessica Allegretti, (Brigham and Women’s Hospital, Boston, MA, USA) around the burden of ulcerative colitis in patients with inadequate response to currently approved treatments, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!